Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
COGT Stock Chart & Stats
$39.45
-$0.07(-0.91%)
At close: 4:00 PM EST
$39.45
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$3.72 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)4.04M
Market Cap
$6.00B
Enterprise Value$1.75B
Total Cash (Recent Filing)$390.89M
Total Debt (Recent Filing)$60.56M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Mar 17, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding152,053,960
10 Day Avg. Volume2,802,293
30 Day Avg. Volume4,037,593
Financial Highlights & Ratios
PEG Ratio-1.92
Price to Book (P/B)3.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.51K
Enterprise Value/Ebitda-5.90
Forecast
1Y Price Target
$43.11Price Target Upside9.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessBezuclastinib achieved 49% ORR in the pivotal APEX study, which positions it as the preferred therapy in ASM with a differentiated profile.
Market OpportunitiesWith three consecutive pivotal trial successes this year, COGT is well-positioned to unlock significant market opportunities.
Safety And TolerabilityThe safety profile is overall favorable, with no patients discontinuing treatment and only 15% needing dose reduction.
Bears Say
Comparative EfficacyThe overall response rate of 49% for Bezuclastinib was lower than the 57% seen with Blueprint/Sanofi's Ayvakit.
Competitive PressureThere was some concern from investors about potential competition from GSK/IDRX's IDRX-42, which is supposed to begin a Phase 3 study for 2L GIST.
Safety ConcernsThe safety profile of bezuclastinib continues to look worse compared to both placebo and Ayvakit.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.72 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market cap is $6.00B.
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Mar 17, 2026 which is in 88 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Nov 03, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.516 by $0.016.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -0.52.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 152,053,960 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.516. Following the earnings report the stock price went down -4.908%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.11 (9.28% Upside)
$43.11 (9.28% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
381.68%
12-Months-Change
Fundamentals
Return on Equity
-95.40%
Trailing 12-Months
Asset Growth
10.92%
Trailing 12-Months
Company Description
Cogent Biosciences
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies to treat genetically driven diseases. The company operates primarily in the biopharmaceutical sector and is dedicated to advancing its core product pipeline, which includes experimental therapies for specific genetic mutations linked to rare disorders and cancers. Cogent Biosciences aims to address unmet medical needs through targeted treatment options, leveraging its expertise in genetic and molecular biology.
COGT Stock 12 Month Forecast
Average Price Target
$43.11
▲(9.28% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---